CT-3D技术引导TACE联合RFA治疗原发性肝癌的效果及对患者血清AFP-L3、DCP、CEA水平的影响  

Effect of CT-3D Technology Guided TACE Combined with RFA in the Treatment of Primary Liver Cancer and Its Influence on Patient’s Serum AFP-L3,DCP,CEA Levels

作　　者：姜海燕[1] 赵春红[1] JIANG Haiyan;ZHAO Chunhong(Jiamusi Central Hospital,Heilongjiang Province,Jiamusi 154002,China;不详)

机构地区：[1]黑龙江省佳木斯市中心医院,黑龙江佳木斯154002

出　　处：《中国医学创新》2022年第16期137-141,共5页Medical Innovation of China

摘　　要：目的:观察CT三维重建(CT-3D)技术引导肝动脉化疗栓塞术(TACE)联合射频消融术(RFA)治疗中晚期原发性肝癌(PLC)的效果及对患者血清甲胎蛋白异质体(AFP-L3)、异常凝血酶原(DCP)、癌胚抗原(CEA)水平的影响。方法:选取2018年7月-2020年7月佳木斯市中心医院收治的60例PLC患者,采用随机数字表法将其分为观察组与对照组,每组30例。对照组采用RFA治疗,观察组在对照组基础上加用CT-3D技术引导下行TACE治疗。比较两组近期疗效,不良反应,血清AFP-L3、DCP、CEA水平及复发转移与生存情况。结果:观察组DCR为83.33%,高于对照组的56.67%(P<0.05)。两组肝区疼痛、发热、胸腔积液、恶心呕吐、骨髓抑制发生率比较,差异均无统计学意义(P>0.05)。治疗4周后,两组血清AFP-L3、DCP、CEA水平均低于治疗前,且观察组均低于对照组,差异均有统计学意义(P<0.05)。随访12~24个月,观察组复发或远处转移率低于对照组,无病生存率、总生存率均高于对照组,平均生存时间长于对照组,差异均有统计学意义(P<0.05)。结论:CT-3D技术引导TACE联合RFA治疗中晚期PLC可进一步提升疗效,降低血清AFP-L3、DCP和CEA水平,减少肿瘤负荷,延长生存期。Objective:To observe the effect of CT three-dimensional reconstruction(CT-3D) technology guided transcatheter hepatic artery chemoembolization(TACE) combined with radiofrequency ablatio(RFA)in the treatment of advanced primary liver cancer(PLC) and its influence on patient’s serum alpha-fetoprotein heterogeneity(AFP-L3),des-γ-carboxy-prothrombin(DCP),carcinoembryonic antigen(CEA) levels.Method:A total of 60 patients with PLC admitted to Jiamusi Central Hospital from July 2018 to July 2020 were selected and divided into the observation group and the control group by random number table method,30 cases in each group.The control group was treated with RFA,and the observation group was treated with CT-3D technology guided TACE treatment on the basis of the control group.The short-term efficacy,adverse reactions,serum AFP-L3,DCP,CEA levels,recurrence,metastasis and survival of two groups were compared.Result:The DCR of the observation group was 83.33%,which was higher than 56.67% of the control group(P<0.05).There were no significant differences in the incidence of pain,fever,pleural effusion,nausea and vomiting,and bone marrow suppression between two groups(P>0.05).After 4 weeks of treatment,the levels of serum AFP-L3,DCP and CEA two groups were lower than those of before treatment,and the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).Follow-up for 12-24 months,the recurrence or distant metastasis rate of the observation group was lower than that of the control group,disease-free survival rate and overall survival rate were higher than those of the control group,and the average survival time was longer than that of the control group,the differences were statistically significant(P<0.05).Conclusion:CT-3D technology guided TACE combined with RFA in the treatment of advanced PLC can further improve the efficacy,reduce serum AFP-L3,DCP and CEA levels,reduce tumor burden,and prolong survival.

关 键 词：CT-3D技术 肝动脉化疗栓塞术 射频消融术 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]